Cassava Sciences, now operating as Filana Therapeutics, reported a FY 2025 net loss of USD 91 million, compared with a FY 2024 net loss of USD 24.3 million. Cash and cash equivalents were USD 95.5 million as of Dec. 31, 2025, down 26% from the prior year-end, with no debt. FY 2025 R&D expenses fell 62% to USD 26.6 million, primarily due to the phase-out of the Alzheimer’s program, while FY 2025 G&A expenses were USD 68.8 million. Net cash used in operations was USD 32.3 million in FY 2025, and the company forecast first-half 2026 net cash use in operations of USD 14-17 million plus a USD 31.25 million payment tied to an estimated securities litigation settlement contingency. CEO Rick Barry said the company is working to address FDA requests related to a clinical hold letter received in December 2025, including additional pre-clinical data and protocol design modifications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001506), on March 12, 2026, and is solely responsible for the information contained therein.
Comments